ArticleFrontiers in bioengineering and biotechnology2026
Study of a novel Ca/P/S-based cement implanted in the osteoporotic goat spine and its clinical application in preventing adjacent vertebral fractures.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic vertebral compression fracture (OVCF) has been increasing over the last decades. In addition to primary OVCF, the adjacent vertebral fracture (AVF) is a frequent serious complication in OVCF patients receiving percutaneous vertebroplasty or kyphoplasty, resulting in poor long-term outcome and recurrent symptoms. The aim of the present study is to investigate the bone regeneration behavior of a novel Ca/P/S-based resorbable cement (Ezechbone® Cement CBC-400) implanted into surgically created vertebral defects of ovariectomized (OVX) goats. Furthermore, the present study provides a preliminary clinical result of minimally invasive injection of this cement into the osteoporotic vertebral bodies adjacent to polymethyl methacrylate (PMMA)-filled primary OVCF bodies as a preventive measure. After implantation, a new bone network developed within the CBC-400 cement, and the cement residues were intimately integrated into the surrounding newly formed bone structures without interposition of fibrous tissues. The newly formed trabecular networks in the OVX_CBC goat were much denser and thicker than the native networks in the OVX goat and those even in the healthy control goat. Under polarized light, a much more randomly oriented, smaller-sized, and more vibrant lamellar bone morphology was observed in the OVX_CBC goat compared to that in the OVX goat, indicating an excellent bone-regenerative efficacy of CBC-400 cement. The treatment results of 10 consecutive clinical OVCF cases, in which their adjacent vertebral bodies preventively augmented with CBC-400, showed that even at an average age of almost 80 years, with half of the patients having prior osteoporotic vertebral fractures and all having multiple comorbidities, none of these patients developed any new AVF in the following 3 years. Prophylactically augmenting adjacent osteoporotic vertebrae with Ezechbone® Cement CBC-400 in combination with conventional PMMA vertebroplasty for OVCF has demonstrated a high potential for effectively reducing the risk of future adjacent vertebral fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.